Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH).

[3][4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.

[4][8] The adverse effects of selexipag are similar to those of intravenous prostacyclins used for pulmonary arterial hypertension.

[9] Selexipag and its active metabolite ACT-333679 act on the prostacyclin receptor of lung tissue, with the latter being 37-fold more potent.

[9] The synthesis of celexipag begins from two inexpensive compounds, glycine hydrochloride and benzil, condensed under basic conditions.